●  Founders

●  Scientific Advisory Board

●  Management

●  Investors

Management

Constellation Pharmaceuticals’ Management and Board of Directors: Unparalleled scientific and business expertise dedicated to the Company’s success in leveraging a new revolution in biology, Epigenetics.

Our initial management team at Constellation is comprised of individuals who have an outstanding and proven track record of founding and building some of the most respected and successful life sciences companies, creating breakthrough science and delivering novel therapeutics.

This team brings the full range of operating and leadership experience across the critical disciplines -- science, technology, business development, marketing and finance necessary build Constellation into a leading biopharmaceutical company.

Constellation Pharmaceuticals’ Management

Mark A. Goldsmith, M.D., Ph.D.
President and Chief Executive Officer

Dr. Mark Goldsmith was announced as the president and CEO of Constellation in August 2009. He previously held senior executive positions in the biotechnology industry and academia. Prior to his appointment at Constellation, Dr. Goldsmith was Senior Executive-in-Residence at Prospect Venture Partners, a leading healthcare venture capital firm. Previously he served as CEO of Cogentus Pharmaceuticals and as senior vice president leading the health care division of Genencor International. Before entering the private sector Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital and was consultant to leading pharmaceutical and biotechnology companies.

Garen Bohlin
Executive Vice President

Garen Bohlin became Executive Vice President of Constellation in January 2010 and is responsible for corporate operations and finance functions. For the past 25 years, he has held senior executive posts in leading biotechnology companies. Most recently prior to joining Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, where he played key roles in the general management of Sirtris, as well as in its initial public offering, the sale of the company to GlaxoSmithKline for over $700 million, and the post-acquisition integration. Previously, he was the founding CEO of Syntonix Pharmaceuticals where he positioned the company for its eventual sale to Biogen Idec. Earlier in his career, he held multiple executive positions at Genetics Institute, where he played an integral role in structuring the sale of Genetics Institute to American Home Products (Wyeth) at an implied valuation of approximately $3 billion.

Edward E. Harlow, Jr., Ph.D.
Chief Scientific Officer

Dr. Harlow joins Constellation Pharmaceuticals in October 2009 from Harvard Medical School, where he has been Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology and Associate Director of the Dana-Farber/Harvard Cancer Center. Dr. Harlow is an internationally recognized leader in cancer biology who is best known for his discoveries regarding the control of cell division and critical changes that allow cancer to develop. Previously he served as Scientific Director for the Massachusetts General Hospital Cancer Center and as Associate Director for Science Policy at the National Cancer Institute, where he helped direct U.S. cancer research planning. Among his numerous scientific honors are election to the National Academy of Sciences and the Institute of Medicine, appointment as Fellow of the American Academy of Arts and Sciences, and receipt of the American Cancer Society’s highest award, the Medal of Honor. He has also served on a number of advisory boards, including the Board of Life Sciences for the National Research Council, External Advisory Boards for UCSF, Stanford, UCLA, and NYU Cancer Center, and Scientific Advisory Boards for the Foundation for Advanced Cancer Studies and several biotechnology and pharmaceutical companies, including Onyx, Alnylam, 3V Biosciences, and Pfizer Pharmaceuticals.

Kerry K. Reinertsen, Ph.D.
Chief Business Officer

Kerry Reinertsen, Ph.D., joins Constellation as Chief Business Officer in January 2010. Dr. Reinertsen is a veteran in the Cambridge and international biotechnology industry and has been responsible for some of the industry’s most transformational alliances. Most recently, she served as Vice President, Corporate and Business Development at Vertex Pharmaceuticals where she was responsible for strategic planning, assessment and execution of collaborations and alliance management. Previously Dr. Reinertsen served for eight years at Millennium Pharmaceuticals where she led the strategic evaluation, structuring and execution of numerous transactions ranging from discovery collaborations to product marketing partnerships, both domestically and internationally. Dr. Reinertsen earned a dual A.B. in Economics and Biochemistry and Molecular Biology from Brown University and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.

Constellation Pharmaceuticals’ Board of Directors

Mark Levin, Chairman
Partner, Third Rock Ventures

Anthony Evnin, Ph.D.
Partner, Venrock

David Goeddel, Ph.D.
Partner, The Column Group

Tom Maniatis, Ph.D.
Professor, Harvard University

Bob Tepper, M.D.
Partner, Third Rock Ventures

Mark A. Goldsmith, M.D., Ph.D.
President and CEO, Constellation